<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>AML | Clinical Hematology</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="Overview of Acute Myeloid Leukemia (AML)  Definition: A group of aggressive hematologic malignancies characterized by the rapid proliferation and accumulation of myeloblasts (immature myeloid...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="AML | Clinical Hematology">
<meta property="og:type" content="book">
<meta property="og:description" content="Overview of Acute Myeloid Leukemia (AML)  Definition: A group of aggressive hematologic malignancies characterized by the rapid proliferation and accumulation of myeloblasts (immature myeloid...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="AML | Clinical Hematology">
<meta name="twitter:description" content="Overview of Acute Myeloid Leukemia (AML)  Definition: A group of aggressive hematologic malignancies characterized by the rapid proliferation and accumulation of myeloblasts (immature myeloid...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Clinical Hematology</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li class="book-part">Erythrocytes</li>
<li><a class="" href="rbc-production.html">RBC Production</a></li>
<li><a class="" href="rbc-function.html">RBC Function</a></li>
<li><a class="" href="rbc-destruction.html">RBC Destruction</a></li>
<li><a class="" href="anemais.html">Anemais</a></li>
<li><a class="" href="microcytic.html">Microcytic</a></li>
<li><a class="" href="iron-deficiency.html">Iron Deficiency</a></li>
<li><a class="" href="chronic-disease.html">Chronic Disease</a></li>
<li><a class="" href="thalassemias.html">Thalassemias</a></li>
<li><a class="" href="sideroblastic.html">Sideroblastic</a></li>
<li><a class="" href="porphyria.html">Porphyria</a></li>
<li><a class="" href="normocytic.html">Normocytic</a></li>
<li><a class="" href="hereditary-hemolytic.html">Hereditary Hemolytic</a></li>
<li><a class="" href="acquired-hemolytic.html">Acquired Hemolytic</a></li>
<li><a class="" href="hypoproliferative.html">Hypoproliferative</a></li>
<li><a class="" href="acute-hemorrhage.html">Acute Hemorrhage</a></li>
<li><a class="" href="macrocytic.html">Macrocytic</a></li>
<li><a class="" href="megaloblastic.html">Megaloblastic</a></li>
<li><a class="" href="nonmegaloblastic.html">Nonmegaloblastic</a></li>
<li><a class="" href="hemoglobinopathies.html">Hemoglobinopathies</a></li>
<li><a class="" href="erythrocytosis.html">Erythrocytosis</a></li>
<li class="book-part">Leukocytes</li>
<li><a class="" href="wbc-production.html">WBC Production</a></li>
<li><a class="" href="wbc-function.html">WBC Function</a></li>
<li><a class="" href="wbc-destruction.html">WBC Destruction</a></li>
<li><a class="" href="benign-disorders.html">Benign Disorders</a></li>
<li><a class="" href="myeloid.html">Myeloid</a></li>
<li><a class="" href="lymphoid.html">Lymphoid</a></li>
<li><a class="" href="myeloid-neoplasia.html">Myeloid Neoplasia</a></li>
<li><a class="active" href="aml.html">AML</a></li>
<li><a class="" href="myelodysplastic.html">Myelodysplastic</a></li>
<li><a class="" href="myeloproliferative.html">Myeloproliferative</a></li>
<li><a class="" href="lymphoid-neoplasia.html">Lymphoid Neoplasia</a></li>
<li><a class="" href="acute-lymphoid.html">Acute Lymphoid</a></li>
<li><a class="" href="chronic-b-cell.html">Chronic B-Cell</a></li>
<li><a class="" href="chronic-t-cell.html">Chronic T-Cell</a></li>
<li><a class="" href="plasma-cell.html">Plasma Cell</a></li>
<li class="book-part">Platelets</li>
<li><a class="" href="plt-production.html">PLT Production</a></li>
<li><a class="" href="plt-function.html">PLT Function</a></li>
<li><a class="" href="plt-destruction.html">PLT Destruction</a></li>
<li><a class="" href="quantitative.html">Quantitative</a></li>
<li><a class="" href="thrombocytopenia-1.html">Thrombocytopenia</a></li>
<li><a class="" href="destruction.html">Destruction</a></li>
<li><a class="" href="production.html">Production</a></li>
<li><a class="" href="pseudo.html">Pseudo</a></li>
<li><a class="" href="thrombocytosis.html">Thrombocytosis</a></li>
<li><a class="" href="qualitative.html">Qualitative</a></li>
<li><a class="" href="von-willebrand.html">von Willebrand</a></li>
<li><a class="" href="bernard-soulier.html">Bernard-Soulier</a></li>
<li><a class="" href="glanzmann.html">Glanzmann</a></li>
<li class="book-part">Hemostasis</li>
<li><a class="" href="coagulation-pathways.html">Coagulation Pathways</a></li>
<li><a class="" href="fibrinolytic-pathways.html">Fibrinolytic Pathways</a></li>
<li><a class="" href="vascular-system.html">Vascular System</a></li>
<li><a class="" href="disorders.html">Disorders</a></li>
<li><a class="" href="factor-deficiencies.html">Factor Deficiencies</a></li>
<li><a class="" href="hereditary.html">Hereditary</a></li>
<li><a class="" href="acquired.html">Acquired</a></li>
<li><a class="" href="inhibitors.html">Inhibitors</a></li>
<li><a class="" href="fibrinolytic.html">Fibrinolytic</a></li>
<li><a class="" href="thrombophilia.html">Thrombophilia</a></li>
<li><a class="" href="dic.html">DIC</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Hematology">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="aml" class="section level1 unnumbered">
<h1>AML<a class="anchor" aria-label="anchor" href="#aml"><i class="fas fa-link"></i></a>
</h1>
<div id="overview-of-acute-myeloid-leukemia-aml" class="section level2 unnumbered">
<h2>
<strong>Overview of Acute Myeloid Leukemia (AML)</strong><a class="anchor" aria-label="anchor" href="#overview-of-acute-myeloid-leukemia-aml"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A group of aggressive hematologic malignancies characterized by the rapid proliferation and accumulation of <em>myeloblasts</em> (immature myeloid cells) in the bone marrow and peripheral blood</li>
<li>
<strong>Hallmark:</strong> &gt;20% blasts in the bone marrow</li>
<li>
<strong>Classification:</strong>
<ul>
<li>The World Health Organization (WHO) classification is the most widely used system and is based on:
<ul>
<li>Morphology</li>
<li>Immunophenotype</li>
<li>Genetic abnormalities (cytogenetics and molecular genetics)</li>
<li>Clinical features</li>
</ul>
</li>
<li>Key Categories (According to WHO):
<ul>
<li>AML with Recurrent Genetic Abnormalities</li>
<li>AML with Myelodysplasia-Related Changes</li>
<li>Therapy-Related AML (t-AML)</li>
<li>AML Not Otherwise Specified (AML-NOS)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Genetic mutations disrupt normal myeloid differentiation, leading to a buildup of myeloblasts</li>
<li>Myeloblasts crowd out normal hematopoietic cells in the bone marrow, causing cytopenias (anemia, thrombocytopenia, neutropenia)</li>
</ul>
</li>
<li>
<strong>Clinical Significance:</strong> Rapidly progressive and life-threatening if untreated</li>
</ul>
</div>
<div id="etiology-and-risk-factors" class="section level2 unnumbered">
<h2>
<strong>Etiology and Risk Factors</strong><a class="anchor" aria-label="anchor" href="#etiology-and-risk-factors"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Genetic Mutations:</strong>
<ul>
<li>AML is typically caused by acquired genetic mutations in hematopoietic stem cells or early myeloid progenitors</li>
<li>These mutations can affect:
<ul>
<li>Transcription factors (e.g., RUNX1, CEBPA)</li>
<li>Signal transduction pathways (e.g., FLT3, RAS)</li>
<li>Epigenetic modifiers (e.g., DNMT3A, TET2)</li>
<li>Spliceosome components (e.g., SF3B1)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Prior Chemotherapy or Radiation Therapy:</strong>
<ul>
<li>Therapy-related AML (t-AML) is a secondary leukemia that develops after exposure to cytotoxic agents or radiation</li>
<li>t-AML often has poor prognosis</li>
</ul>
</li>
<li>
<strong>Underlying Hematologic Disorders:</strong>
<ul>
<li>Myelodysplastic syndromes (MDS) can transform into AML</li>
<li>Myeloproliferative neoplasms (MPNs) can transform into AML</li>
</ul>
</li>
<li>
<strong>Genetic Predisposition:</strong>
<ul>
<li>Certain inherited genetic syndromes increase the risk of developing AML (e.g., Fanconi anemia, Down syndrome)</li>
</ul>
</li>
<li>
<strong>Environmental Factors:</strong>
<ul>
<li>Exposure to benzene or other chemicals</li>
<li>Smoking</li>
</ul>
</li>
</ul>
</div>
<div id="classification-of-aml-who-2016" class="section level2 unnumbered">
<h2>
<strong>Classification of AML (WHO 2016)</strong><a class="anchor" aria-label="anchor" href="#classification-of-aml-who-2016"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<p><strong>AML with Recurrent Genetic Abnormalities:</strong></p>
<ul>
<li>
<strong>AML with t(8;21)(q22;q22.1); <em>RUNX1-RUNX1T1</em></strong>
<ul>
<li>Favorable prognosis</li>
<li>Often associated with Auer rods and maturation</li>
</ul>
</li>
<li>
<strong>AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <em>CBFB-MYH11</em></strong>
<ul>
<li>Favorable prognosis</li>
<li>Often associated with increased eosinophils in the bone marrow</li>
</ul>
</li>
<li>
<strong>Acute Promyelocytic Leukemia (APL) with t(15;17)(q24.1;q21.1); <em>PML-RARA</em></strong>
<ul>
<li>Good prognosis with appropriate treatment</li>
<li>Associated with disseminated intravascular coagulation (DIC)</li>
<li>Abnormal promyelocytes with Auer rods</li>
</ul>
</li>
<li>
<strong>AML with t(9;11)(p21.3;q23.3); <em>MLLT3-KMT2A</em></strong>
<ul>
<li>Intermediate prognosis</li>
<li>Often associated with monocytic differentiation</li>
</ul>
</li>
<li><strong>AML with t(v;11q23.3); <em>KMT2A</em> rearranged:</strong></li>
<li><strong>AML with t(6;9)(p23;q34.1); <em>DEK-NUP214</em></strong></li>
<li><strong>AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <em>GATA2, MECOM</em></strong></li>
<li><strong>AML with t(1;22)(p13.3;q13.1); <em>RBM15-MKL1</em></strong></li>
</ul>
</li>
<li>
<p><strong>AML with Myelodysplasia-Related Changes:</strong></p>
<ul>
<li>History of myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN)</li>
<li>Multilineage dysplasia in the bone marrow (dysplasia in ≥50% of cells in at least 2 cell lineages)</li>
<li>Specific cytogenetic abnormalities</li>
</ul>
</li>
<li>
<p><strong>Therapy-Related AML (t-AML):</strong></p>
<ul>
<li>Occurs after exposure to cytotoxic chemotherapy or radiation therapy</li>
<li>Often associated with specific cytogenetic abnormalities and poor prognosis</li>
</ul>
</li>
<li>
<p><strong>AML Not Otherwise Specified (AML-NOS):</strong></p>
<ul>
<li>AML cases that do not meet the criteria for the other WHO subtypes</li>
<li>Subclassified based on morphology:
<ul>
<li>AML with minimal differentiation</li>
<li>AML without maturation</li>
<li>AML with maturation</li>
<li>Acute myelomonocytic leukemia</li>
<li>Acute monoblastic/monocytic leukemia</li>
<li>Acute erythroid leukemia</li>
<li>Acute megakaryoblastic leukemia</li>
<li>Acute basophilic leukemia</li>
<li>Acute panmyelosis with myelofibrosis</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="clinical-features" class="section level2 unnumbered">
<h2>
<strong>Clinical Features</strong><a class="anchor" aria-label="anchor" href="#clinical-features"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Symptoms of Anemia:</strong>
<ul>
<li>Fatigue</li>
<li>Weakness</li>
<li>Pallor (pale skin)</li>
<li>Shortness of breath</li>
</ul>
</li>
<li>
<strong>Symptoms of Thrombocytopenia:</strong>
<ul>
<li>Bleeding (e.g., nosebleeds, gum bleeding, easy bruising)</li>
<li>Petechiae (small, pinpoint hemorrhages)</li>
<li>Ecchymoses (bruises)</li>
</ul>
</li>
<li>
<strong>Symptoms of Neutropenia:</strong>
<ul>
<li>Frequent infections</li>
<li>Fever</li>
<li>Sore throat</li>
</ul>
</li>
<li>
<strong>Other Symptoms:</strong>
<ul>
<li>Bone pain</li>
<li>Splenomegaly (enlarged spleen)</li>
<li>Hepatomegaly (enlarged liver)</li>
<li>Lymphadenopathy (swollen lymph nodes) - less common in AML than ALL</li>
<li>Gingival hyperplasia (swelling of the gums), especially in acute monocytic leukemia</li>
<li>Skin infiltration (leukemia cutis)</li>
<li>Disseminated Intravascular Coagulation (DIC):
<ul>
<li>Can occur, especially in acute promyelocytic leukemia (APL)</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="laboratory-findings-3" class="section level2 unnumbered">
<h2>
<strong>Laboratory Findings</strong><a class="anchor" aria-label="anchor" href="#laboratory-findings-3"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Complete Blood Count (CBC):</strong>
<ul>
<li>Hemoglobin (HGB): Decreased (anemia)</li>
<li>Hematocrit (HCT): Decreased</li>
<li>Red Blood Cell Count (RBC): Decreased</li>
<li>Platelet Count: Decreased (thrombocytopenia)</li>
<li>White Blood Cell Count (WBC): Variable; can be low, normal, or elevated
<ul>
<li>Neutropenia: Often present, but some patients may have elevated neutrophil counts</li>
</ul>
</li>
<li>Presence of blasts in the peripheral blood (usually &gt;20% of WBCs)</li>
</ul>
</li>
<li>
<strong>Peripheral Blood Smear:</strong>
<ul>
<li>Myeloblasts: Large, immature cells with:
<ul>
<li>High nucleus-to-cytoplasm (N:C) ratio</li>
<li>Fine chromatin</li>
<li>Prominent nucleoli</li>
<li>Auer rods: Rod-shaped inclusions in the cytoplasm (especially in AML with t(15;17))</li>
</ul>
</li>
<li>Decreased mature granulocytes and platelets</li>
</ul>
</li>
<li>
<strong>Coagulation Studies (PT, aPTT, Fibrinogen, D-dimer):</strong>
<ul>
<li>May be abnormal, especially in acute promyelocytic leukemia (APL) due to disseminated intravascular coagulation (DIC)</li>
</ul>
</li>
<li>
<strong>Bone Marrow Aspiration and Biopsy:</strong>
<ul>
<li>Hypercellular marrow with &gt;20% blasts</li>
<li>Dysplastic changes in one or more cell lines</li>
<li>Special stains:
<ul>
<li>Myeloperoxidase (MPO): Positive in myeloblasts</li>
<li>Sudan Black B (SBB): Positive in myeloblasts</li>
<li>Esterase stains: Differentiate myeloblasts from monoblasts</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Flow Cytometry Immunophenotyping:</strong>
<ul>
<li>Identifies cell surface markers on the blasts to determine the lineage (myeloid) and subtype of AML</li>
<li>Common markers:
<ul>
<li>Myeloid markers: CD13, CD33, CD117, myeloperoxidase (MPO), CD15</li>
<li>Stem cell markers: CD34, HLA-DR</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Cytogenetic Analysis:</strong>
<ul>
<li>Identifies chromosomal abnormalities (e.g., translocations, inversions, deletions) that are used for diagnosis and prognosis</li>
</ul>
</li>
<li>
<strong>Molecular Testing:</strong>
<ul>
<li>Detects gene mutations (e.g., FLT3, NPM1, CEBPA) that are used for diagnosis, prognosis, and treatment planning</li>
</ul>
</li>
</ul>
</div>
<div id="diagnosis" class="section level2 unnumbered">
<h2>
<strong>Diagnosis</strong><a class="anchor" aria-label="anchor" href="#diagnosis"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Based on the Following Criteria:</strong>
<ul>
<li>Bone Marrow Aspiration and Biopsy: &gt;20% blasts in the bone marrow</li>
<li>Peripheral Blood Smear: Presence of blasts</li>
<li>Immunophenotyping: Identifies the lineage and subtype of AML</li>
<li>Cytogenetic Analysis: Detects chromosomal abnormalities</li>
<li>Molecular Testing: Detects gene mutations</li>
</ul>
</li>
</ul>
</div>
<div id="treatment" class="section level2 unnumbered">
<h2>
<strong>Treatment</strong><a class="anchor" aria-label="anchor" href="#treatment"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<p><strong>Goals of Treatment:</strong></p>
<ul>
<li>Achieve complete remission (CR): Eradication of blasts from the bone marrow and restoration of normal hematopoiesis</li>
<li>Prevent relapse</li>
<li>Prolong survival</li>
</ul>
</li>
<li>
<p><strong>Phases of Treatment:</strong></p>
<ul>
<li>Induction Chemotherapy:
<ul>
<li>Intensive chemotherapy to rapidly reduce the number of leukemic cells in the bone marrow and peripheral blood</li>
<li>Common regimens:
<ul>
<li>“7+3” (cytarabine for 7 days and daunorubicin or idarubicin for 3 days)</li>
</ul>
</li>
<li>Patients are at high risk for complications (e.g., infection, bleeding) during induction</li>
</ul>
</li>
<li>Consolidation Therapy:
<ul>
<li>Administered after achieving remission to eliminate any remaining leukemic cells and prevent relapse</li>
<li>Options:
<ul>
<li>Chemotherapy</li>
<li>Hematopoietic Stem Cell Transplantation (HSCT):
<ul>
<li>Allogeneic HSCT (from a matched donor) is the preferred consolidation therapy for many patients with high-risk AML</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Treatment of Acute Promyelocytic Leukemia (APL):</strong></p>
<ul>
<li>All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) is the preferred treatment for most patients with APL</li>
<li>This combination therapy targets the PML-RARA fusion protein and promotes differentiation of promyelocytes</li>
<li>Chemotherapy may be added in high-risk cases</li>
</ul>
</li>
<li>
<p><strong>Supportive Care:</strong></p>
<ul>
<li>Transfusions (RBCs and platelets) to manage anemia and thrombocytopenia</li>
<li>Antibiotics and antifungals to treat infections</li>
<li>Growth factors (e.g., G-CSF) to stimulate neutrophil production</li>
<li>Management of tumor lysis syndrome (TLS): A metabolic complication caused by the rapid breakdown of leukemic cells</li>
</ul>
</li>
</ul>
</div>
<div id="prognosis" class="section level2 unnumbered">
<h2>
<strong>Prognosis</strong><a class="anchor" aria-label="anchor" href="#prognosis"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<p><strong>Factors Influencing Prognosis:</strong></p>
<ul>
<li>Cytogenetic Abnormalities: Certain chromosomal abnormalities are associated with favorable or unfavorable outcomes</li>
<li>Gene Mutations: The presence of certain gene mutations (e.g., FLT3-ITD) is associated with poorer prognosis, while others (e.g., NPM1) are associated with more favorable outcomes</li>
<li>Age: Younger patients generally have better outcomes than older patients</li>
<li>Performance Status: Overall health and fitness of the patient</li>
<li>Response to Induction Chemotherapy: Achievement of complete remission is a key prognostic factor</li>
</ul>
</li>
<li>
<p><strong>Risk Stratification:</strong></p>
<ul>
<li>Patients are classified into risk groups (favorable, intermediate, or adverse) based on cytogenetic and molecular abnormalities</li>
<li>Risk stratification guides treatment decisions and helps predict the likelihood of achieving long-term remission</li>
</ul>
</li>
</ul>
</div>
<div id="key-laboratory-findings-5" class="section level2 unnumbered">
<h2>
<strong>Key Laboratory Findings</strong><a class="anchor" aria-label="anchor" href="#key-laboratory-findings-5"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>CBC:</strong>
<ul>
<li>Anemia</li>
<li>Thrombocytopenia</li>
<li>Neutropenia</li>
<li>Presence of blasts in the peripheral blood</li>
</ul>
</li>
<li>
<strong>Peripheral Blood Smear:</strong>
<ul>
<li>Myeloblasts</li>
<li>Auer rods (in some cases)</li>
</ul>
</li>
<li>
<strong>Bone Marrow Examination:</strong>
<ul>
<li>Hypercellular marrow with &gt;20% blasts</li>
</ul>
</li>
<li>
<strong>Flow Cytometry:</strong>
<ul>
<li>Identifies cell surface markers on the blasts</li>
</ul>
</li>
<li>
<strong>Cytogenetic Analysis:</strong>
<ul>
<li>Detects chromosomal abnormalities</li>
</ul>
</li>
<li>
<strong>Molecular Testing:</strong>
<ul>
<li>Detects gene mutations</li>
</ul>
</li>
</ul>
</div>
<div id="key-terms-26" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-26"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Acute Myeloid Leukemia (AML):</strong> An aggressive leukemia characterized by &gt;20% blasts in the bone marrow</li>
<li>
<strong>Myeloblast:</strong> Immature myeloid cell</li>
<li>
<strong>Auer Rods:</strong> Rod-shaped inclusions in the cytoplasm of myeloblasts</li>
<li>
<strong>Cytopenia:</strong> Deficiency of blood cells (e.g., anemia, thrombocytopenia, neutropenia)</li>
<li>
<strong>Complete Remission (CR):</strong> Eradication of blasts from the bone marrow and restoration of normal hematopoiesis</li>
<li>
<strong>Induction Chemotherapy:</strong> Initial intensive chemotherapy to achieve remission</li>
<li>
<strong>Consolidation Therapy:</strong> Treatment to prevent relapse after achieving remission</li>
<li>
<strong>Hematopoietic Stem Cell Transplantation (HSCT):</strong> Procedure to replace damaged bone marrow with healthy stem cells</li>
<li>
<strong>Cytogenetic Analysis:</strong> The study of chromosomes and their abnormalities</li>
<li>
<strong>Molecular Testing:</strong> Techniques to detect gene mutations and other molecular abnormalities</li>
</ul>
</div>
</div>
  <div class="chapter-nav">
<div class="prev"><a href="myeloid-neoplasia.html">Myeloid Neoplasia</a></div>
<div class="next"><a href="myelodysplastic.html">Myelodysplastic</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#aml">AML</a></li>
<li><a class="nav-link" href="#overview-of-acute-myeloid-leukemia-aml">Overview of Acute Myeloid Leukemia (AML)</a></li>
<li><a class="nav-link" href="#etiology-and-risk-factors">Etiology and Risk Factors</a></li>
<li><a class="nav-link" href="#classification-of-aml-who-2016">Classification of AML (WHO 2016)</a></li>
<li><a class="nav-link" href="#clinical-features">Clinical Features</a></li>
<li><a class="nav-link" href="#laboratory-findings-3">Laboratory Findings</a></li>
<li><a class="nav-link" href="#diagnosis">Diagnosis</a></li>
<li><a class="nav-link" href="#treatment">Treatment</a></li>
<li><a class="nav-link" href="#prognosis">Prognosis</a></li>
<li><a class="nav-link" href="#key-laboratory-findings-5">Key Laboratory Findings</a></li>
<li><a class="nav-link" href="#key-terms-26">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Hematology/blob/main/02-08-leukocyte-neoplasia-myeloid-aml.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Hematology/edit/main/02-08-leukocyte-neoplasia-myeloid-aml.Rmd">Edit this page <i class="fab fa-github"></i></a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3" style="text-align: center; flex: 100%; max-width: 100%;">
    <p>Written by Brett M. Rice | Updated 2025-02-20 | Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div>

  <!--div class="col-12 col-md-6 mt-3">
    <p>Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div-->

</div></div>
</footer>
</body>
</html>
